ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page
Pyrantel
Tetrahydropyrimidine Derivatives
CA Health Canada
- Drug class
- Tetrahydropyrimidine Derivatives
- Availability
- See label
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 4
Overview
Pyrantel is an active pharmaceutical ingredient in the Tetrahydropyrimidine Derivatives group (P02CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 4 | May 15, 2026 |
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [1].
Sources & citations
- [1]Health Canada (DPD) · 01944363 · revised May 15, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.